Abstract:2576 Background: Tumor microenvironment (TME) heterogeneity leads to the discrepancy of survival prognosis and clinical treatment response for HCC patients. Although the documented molecular subtypes moderately describe the TME heterogeneity and characteristics, their clinical application is constrained by several issues. Methods: We integrated three single-cell datasets from 39 HCC patients to describe the TME landscape and identified prognosis-related cell subclusters. Unsupervised clustering of subcluster-specific markers (SSMs) was performed to generate transcriptomic subtypes. The predictive value of these molecular subtypes for prognosis and treatment response was explored in multiple external HCC cohorts and Xiangya real-world HCC cohort with patients who received immune checkpoint blockade (ICB) therapy. Cancer stemness was estimated using bioinformatic methods and in vivo and in vitro experiments. The features of TME were further validated using single-cell RNA-seq and immune repertoire sequencing, mass cytometry (CyTOF) and multiplex immunofluorescence (mIF). Ultimately, we constructed prognosis-related score (PRS)based on machine learning algorithm, and identified the potential therapeutic targets and agents for high-PRS patients. Results: The comprehensive single-cell analysis provided a high-resolution depiction of TME heterogeneity in HCC and confirmed 6 cell subclusters of prognostic relevance. Five transcriptomic subtypes were constructed using SSMs, which possessed different clinical prognosis, stemness characteristics, immune landscape and therapeutic responses. Class 1 indicated an inflamed phenotype with better clinical outcomes, while Class 2 and class 4 demonstrated immune-deserted phenotypes lacking T cells infiltration. Class 5 and class 3 indicated inhibitory tumor immune microenvironment enriched regulatory T cells and suppressive immune checkpoints. Multiple therapeutic cohorts suggested that Class 5 and class 3 were sensitive to ICB and targeted therapy, while Class 1 and Class 2 were more responsive to transcatheter arterial chemoembolization treatment (TACE). Class 4 displayed resistant to all conventional HCC therapies. The PRS performed well in prognostic prediction in multiple HCC cohorts. Four potential therapeutic agents and four targets were further identified for high-PRS HCC patients. Conclusions: Our study generated a clinically valid molecular classification, thereby providing guidance for precision medicine in HCC patients.

Outcome-guided Sparse K-means for Disease Subtype Discovery via Integrating Phenotypic Data with High-dimensional Transcriptomic Data

Outcome-guided Bayesian clustering for disease subtype discovery using high-dimensional transcriptomic data

Outcome-Guided Disease Subtyping for High-Dimensional Omics Data

Clinical outcome-guided deep temporal clustering for disease progression subtyping

Robust correlation estimation and UMAP assisted topological analysis of omics data for disease subtyping

Robust clustering of noisy high-dimensional gene expression data for patients subtyping

Sparse integrative clustering of multiple omics data sets

Subtype-DCC: decoupled contrastive clustering method for cancer subtype identification based on multi-omics data

Identification of Molecular Subtypes for Integrated Multi-Omics Analysis for Use in Guiding Precision Medicine in Hepatocellular Carcinoma.

Identifying cancer subtypes in glioblastoma by combining genomic, transcriptomic and epigenomic data

A Contrastive-Learning-Based Deep Neural Network for Cancer Subtyping by Integrating Multi-Omics Data

Cancer subtype identification by multi-omics clustering based on interpretable feature and latent subspace learning

Supervised Graph Clustering for Cancer Subtyping Based on Survival Analysis and Integration of Multi-Omic Tumor Data

Unravelling the hidden heterogeneities of diffuse large B-cell lymphoma based on coupled two-way clustering

Gene-SGAN: a method for discovering disease subtypes with imaging and genetic signatures via multi-view weakly-supervised deep clustering

Gene-SGAN: discovering disease subtypes with imaging and genetic signatures via multi-view weakly-supervised deep clustering

Multi-omics subtyping pipeline for chronic obstructive pulmonary disease

Robust nonparametric integrative analysis to decipher heterogeneity and commonality across subgroups using sparse boosting

Clustering of Transcriptomic Data for the Identification of Cancer Subtypes

Multi-view contrastive clustering for cancer subtyping using fully and weakly paired multi-omics data

Multi-scale supervised clustering-based feature selection for tumor classification and identification of biomarkers and targets on genomic data